Croissy Sur Seine, 
  • Booth: 500

NOTOCORD is now part of the Instem group.

NOTOCORD Systems is a leading provider of software solutions designed to acquire and analyze data in preclinical studies (discovery, early safety and toxicology).

We are now part of the Instem group, please stop by and hear more!

Our featured solutions include:
NOTOCORD-fps 3.0, our software platform quickly and easily measure iPSCs field potentials from MEA devices. NOTOCORD-sense™ aimed to replace ultimately and extend NOTOCORD-hem that provides fast and high-quality analysis for studies covering cardiovascular, respiratory, electrophysiology and nervous system.

Brands: NOTOCORD-hem, NOTOCORD-fps, NOTOCORD-sense platform

 Press Releases

  • NOTOCORD Joining Instem Group to Help Drive Growth & Next Stage of Innovation

    CONSHOHOCKEN, PA - (BUSINESS WIRE) – September 5, 2016 - -Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has acquired NOTOCORD® as part of its mission to further consolidate and harmonize key application areas that are helping customers streamline their research and development processes.

    Based in Paris, France, with a presence in the United States, NOTOCORD provides software solutions for data acquisition and analysis in preclinical studies and is a recognized leader in cardiovascular, respiratory, electrophysiology and nervous system research areas. NOTOCORD solutions are used by pharmaceutical companies, contract research laboratories, hospitals and academic research centers around the world.

    Instem views the acquisition of NOTOCORD as another important and tangible step in its mission to help clients bring life enhancing products to market faster.

    NOTOCORD is a well-respected name in the life sciences software market and its solutions are used every day by top scientists for new drug development research within discovery, safety pharmacology and toxicology studies. Its most widely known solution, NOTOCORD-hem™, is a leading telemetry-based safety pharmacology data collection & analysis system used in preclinical studies.

    “The combined customers of NOTOCORD and Instem will be gaining a real advantage,” comments Philippe Zitoun, founder and Chief Executive Officer at NOTOCORD. “Our mission all along was to create technology that was easier and faster to use so our clients can do what they do best, every day. Since we were founded, we have relied on innovative and creative thinking to understand tomorrow’s needs in the marketplace. Becoming part of Instem will allow us to deliver more value, more quickly to more users everywhere. The entire team here at NOTOCORD is excited to be supported by a full complement of resources across Instem’s international offices. Instem shares in our commitment to excellence and is also well known for highly satisfied clients throughout all of the segments that they serve.”